The platelet transfusion trigger trial (PTTT): A multivariate analysis of risk factors for major bleeding in acute myeloid leukemia (AML)

被引：0
|
作者：
Finazzi, G [1 ]
机构：
[1] OSPED RIUNITI BERGAMO,DIV HEMATOL,I-24100 BERGAMO,ITALY
来源：
THROMBOSIS AND HAEMOSTASIS | 1997年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：HI8 / HI8
页数：2
相关论文
共 50 条
  • [1] Interim report from the platelet transfusion trigger trial (PTTT): A prospective controlled study on bleeding risk in acute myeloblastic leukemia (AML) patients randomized to be transfused at <=10 versus <=20x10(9)/L platelets.
    Rebulla, P
    Mandelli, F
    [J]. BLOOD, 1996, 88 (10) : 1761 - 1761
  • [2] MDR expression in acute myeloid leukemia (AML): Major prognosis significance in multivariate analysis.
    Hunault, M
    Zhou, D
    Ramon, S
    Delmer, A
    Cadiou, M
    Perrot, JY
    Marie, JP
    Zittoun, R
    [J]. BLOOD, 1995, 86 (10) : 1062 - 1062
  • [3] Dysfunctions in Primary Hemostasis as Additional Risk Factors of Bleeding in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Stupakova, Zinaida
    Dyagil, Irina
    Martina, Zoya
    Tovstohan, Anzhela
    Karnabeda, Oksana
    Melnyk, Ulyana
    Novosad, Olga
    Sobchenko, Andrii
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S183 - S183
  • [4] Risk Factors for Bleeding: A Modelling Analysis of the TOPPS Randomized Controlled Trial of Prophylactic Platelet Transfusion
    Wood, Erica M.
    Hudson, Cara
    Estcourt, Lise
    Johnson, Rachel
    Stanworth, Simon J.
    [J]. BLOOD, 2014, 124 (21)
  • [5] Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness
    Chellaiya, Gayathiri K.
    Nair, Chandran K.
    Raghavan, Vineetha
    Pandian, R. Jesu
    Vinod, Roshan
    Murugesan, Mohandoss
    [J]. ASIAN JOURNAL OF TRANSFUSION SCIENCE, 2021, 15 (01) : 90 - 93
  • [6] Factors Affecting Transfusion Utilization in Acute Myeloid Leukemia (AML) Patients Undergoing Initial Therapy
    Lee, Sangmin
    Parra, Priscilla
    Udoyen, Idongessit
    Grover, Kartikey
    Kane, Kathleen
    Desai, Pinkal
    Samuel, Michael
    Ritchie, Ellen K.
    Roboz, Gail J.
    Cushing, Melissa M.
    [J]. BLOOD, 2017, 130
  • [7] Dysfunctions in primary hemostasis as an additional risk factors of bleeding in patients with newly diagnosed acute myeloid leukemia (AML): Ukrainian prospective analysis.
    Stupakova, Zinaida
    Dyagil, Iryna
    Martina, Zoya
    Karnabeda, Oksana
    Melnyk, Ulyana
    Novosad, Olga
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S5 - S6
  • [8] Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)
    Blum, William
    Klisovic, Rebecca B.
    Garzon, Ramiro
    Walker, Alison
    Schwind, Sebastian
    Liu, Shujun
    Schaaf, Larry
    Garr, Celia
    Devine, Steven M.
    Greyer, Michael R.
    Byrd, John C.
    Marcucci, Guido
    [J]. BLOOD, 2010, 116 (21) : 1349 - 1349
  • [9] Clinical efficacy of platelet transfusion therapy in patients with leukemia and analysis of risk factors for ineffective transfusion
    Chen, Li
    Zhou, Hao
    Guo, Bo
    Guan, Zheng
    [J]. ONCOLOGY LETTERS, 2020, 19 (03) : 2554 - 2561
  • [10] Risk factors and prognostic analysis of acute myeloid leukemia in children
    Xin, Xiaoli
    Zhu, Huafeng
    Chang, Ziwei
    Feng, Miaojuan
    Gao, Shan
    Hou, Liping
    Su, Xiaoli
    [J]. JOURNAL OF BUON, 2021, 26 (01): : 166 - 172
12345